Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tri K Nguyen

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Molecular Cancer Therapeutics|December 24, 2013
Dinaciclib (SCH727965) inhibits the unfolded protein response through a CDK1- and 5-dependent mechanismTri K Nguyen, Steven Grant
Leukemia Research|February 17, 2006
Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/AblGirija Dasmahapatra, Tri K Nguyen, Paul Dent, et al.
Leukemia Research|May 14, 2019
Corrigendum to "Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl" [Leuk. Res. 30 (2006) 1263-1272]Girija Dasmahapatra, Tri K Nguyen, Paul Dent, et al.
Molecular Pharmacology|June 28, 2007
The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulationMohamed Rahmani, Tri K Nguyen, Paul Dent, et al.
Blood|January 16, 2007
MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825Tri K Nguyen, Mohamed Rahmani, Hisashi Harada, et al.
Transportation Research. Part A, Policy and Practice|June 1, 2022
Enhancing Covid-19 virus spread modeling using an activity travel modelTri K Nguyen, Nam H Hoang, Graham Currie, et al.
Leukemia Research|February 2, 2010
Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosisTri K Nguyen, Nicholas Jordan, Jonathan Friedberg, et al.
Blood|May 29, 2008
Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylateYun Dai, Shuang Chen, Charis A Venditti, et al.
Molecular and Cellular Biology|June 6, 2007
The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stressMohamed Rahmani, Eric Maynard Davis, Timothy Ryan Crabtree, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2006
Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylateTri K Nguyen, Mohamed Rahmani, Ning Gao, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Molecular Cancer Therapeutics|December 24, 2013
Dinaciclib (SCH727965) inhibits the unfolded protein response through a CDK1- and 5-dependent mechanismTri K Nguyen, Steven Grant
Leukemia Research|February 17, 2006
Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/AblGirija Dasmahapatra, Tri K Nguyen, Paul Dent, et al.
Leukemia Research|May 14, 2019
Corrigendum to "Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl" [Leuk. Res. 30 (2006) 1263-1272]Girija Dasmahapatra, Tri K Nguyen, Paul Dent, et al.
Molecular Pharmacology|June 28, 2007
The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulationMohamed Rahmani, Tri K Nguyen, Paul Dent, et al.
Blood|January 16, 2007
MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825Tri K Nguyen, Mohamed Rahmani, Hisashi Harada, et al.
Transportation Research. Part A, Policy and Practice|June 1, 2022
Enhancing Covid-19 virus spread modeling using an activity travel modelTri K Nguyen, Nam H Hoang, Graham Currie, et al.
Leukemia Research|February 2, 2010
Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosisTri K Nguyen, Nicholas Jordan, Jonathan Friedberg, et al.
Blood|May 29, 2008
Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylateYun Dai, Shuang Chen, Charis A Venditti, et al.
Molecular and Cellular Biology|June 6, 2007
The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stressMohamed Rahmani, Eric Maynard Davis, Timothy Ryan Crabtree, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2006
Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylateTri K Nguyen, Mohamed Rahmani, Ning Gao, et al.
Pageof 1